Lygature Revenue and Competitors

Claim your profile

Utrecht, Netherlands

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Lygature's estimated annual revenue is currently $12.7M per year.(i)
  • Lygature's estimated revenue per employee is $201,000

Employee Data

  • Lygature has 63 Employees.(i)
  • Lygature grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M630%N/AN/A
#2
$258.3M1285-2%N/AN/A
#3
$2.4M129%N/AN/A
#4
$258.3M1285-2%N/AN/A
#5
$16.7M83-31%N/AN/A
#6
$75.6M376132%N/AN/A
#7
$55.5M27611%N/AN/A
#8
$34.4M1719%N/AN/A
#9
$27.7M1381%N/AN/A

Lygature drives the development of new medical solutions for patients by managing public-private partnerships that bring together industry, academia and society. Every day we pioneer solutions in the areas of medical technology and pharmacotherapy to serve patients worldwide. Lygature is a not-for-profit organization based in the Netherlands. We build upon the legacy of the Center for Translational Molecular Medicine (CTMM) and Top Institute Pharma (TI Pharma).

keywords:N/A

N/A

Total Funding

63

Number of Employees

$12.7M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Lygature News

27-Aug-19 - Fraunhofer and grit42 join forces in the global fight against ...

... the global umbrella of the AMR Accelerator, the Gram-Negative Antibacterials NOW (GNA NOW) consortium, led by Evotec SE and Lygature, ...

2-Aug-19 - New IMI project 'GNA Now' kicks off its battle against ...

The new GNA NOW project, led by Evotec SE, managed by Lygature and funded by the Innovative Medicines Initiative (IMI), will work on the ...

4-Aug-19 - Contract research organizations profit from nonprofits' drug ...

In a project with the Dutch drug-discovery nonprofit Top Institute Pharma, now a subsidiary of the nonprofit Lygature, MercachemSyncom ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.2M6380%N/A
#2
$11.4M639%N/A
#3
$12.9M6597%N/A
#4
N/A676%N/A
#5
$12.9M6824%N/A